Company news
NFL Biosciences SA news in 2025
NFL Biosciences SA's news releases, calls and decks from 2025, newest first.
NFL Biosciences Obtains Complementary Characterization Results for NFL-101, its first-in-class Drug Candidate for Smoking Cessation, and Prepares a New Patent Application
December 8, 2025
NFL Biosciences Presents the Agenda for Results Expected by Regulatory Agencies and Potential Pharmaceutical Partners
November 12, 2025
NFL Biosciences Outlines Its Development Plan for NFL-101 in Smoking Cessation Following Receipt of Scientific Advice From Several European Agencies and the U.S. FDA
October 20, 2025
NFL Biosciences Reports Its 2025 Half-Year Results and Provides an Update on Its Development
October 16, 2025
NFL Biosciences Announces the Publication of the Results of Its Phase II Clinical Trial CESTO II Evaluating NFL-101 in Smoking Cessation in Nicotine & Tobacco Research, the Official Journal of the Society for Research on Nicotine and Tobacco (SRNT)
September 1, 2025
NFL Biosciences Announces a Scientific Collaboration with McLean Hospital (Boston, USA) to Further Investigate the Mechanism of Action of NFL-101
July 28, 2025
NFL Biosciences Secures Initial Non-Dilutive Funding of €1.2 Million, Adding to Its Recent Capital Increase, to Advance the Development of NFL-101, Its First-in-Class Treatment for Tobacco Addiction
July 22, 2025
NFL Biosciences strengthens its clinical leadership by expanding Dr. Yannick Plétan’s role as Chief Medical Officer as part of the acceleration of its clinical development program for NFL-101 in smoking cessation
July 3, 2025
NFL Biosciences announces the success of its capital increase capped at €3 million
May 23, 2025
NFL Biosciences launches a capital increase of approximately €2.2 million
May 22, 2025
NFL Biosciences strengthens its scientific committee with world-class experts to support the Phase 3 development of NFL-101, its first-in-class therapy for tobacco addiction
May 12, 2025
NFL Biosciences announces results from a new study conducted with the CEA providing further insight into the effects of NFL-101, its first-in-class treatment for tobacco addiction, and highlighting its prolonged activity
May 5, 2025
NFL Biosciences: Marex Group initiates coverage of NFL Biosciences with a Buy rating
April 24, 2025